An advisory committee from the European Medicines Agency (EMA) has upheld its opinion against granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for amyotrophic lateral sclerosis (ALS) in the European Union. The decision was taken in a meeting by the Committee for Medicinal…
The first patient has been dosed in a Phase 1/2 clinical trial of AMT-162, the one-time gene therapy in development by uniQure for treating amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, when the condition is thus known as SOD1-ALS. The open-label EPISOD1 clinical…
An ultra-high dose of mecobalamin, a naturally occurring form of vitamin B12, has been approved in Japan under the brand name Rozebalamin to treat amyotrophic lateral sclerosis (ALS). The therapy, which will be manufactured and marketed by Eisai, is intended to slow functional decline in people with the…
The Scott-Morgan Foundation (SMF), a nonprofit that’s pioneering assistive technology innovation, will lead a new initiative using artificial intelligence (AI) technologies to help people with diseases like amyotrophic lateral sclerosis (ALS) to better communicate and maintain their sense of identity. “We live in a world where millions are…
A Texas Children’s Hospital investigator has received a $2.4 million grant for a study that seeks to understand whether mechanisms used by bacteria to hide from the immune system can be explored to ease inflammation in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Steven Boeynaems, PhD, an investigator…
A treatment candidate from Revalesio named RNS60 protected motor neurons from damage in a mouse model of amyotrophic lateral sclerosis (ALS) linked with accumulating toxic TDP-43 protein clumps. It also showed it could improve the health of mitochondria, the cells’ powerhouses that are abnormal in ALS, and reduce…
NeuroSense Therapeutics has initiated the process of applying to Canada’s regulators for early marketing approval of PrimeC in treating amyotrophic lateral sclerosis (ALS), based on positive findings in a Phase 2b clinical trial. The application will be filed under Health Canada’s Notice of Compliance with Conditions policy, which could…
Avextra is set to launch a Phase 2 trial in Italy to test a cannabis-based oral medication for the management of symptoms in people with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The announcement comes after clearance from both the Italian Medicines Agency and the Ministry of…
Researchers have developed a type of gene therapy that can rescue the function of the TDP-43 protein in diseased nerve cells in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases while leaving healthy cells untouched. The approach uses problematic sequences called cryptic exons that are only present in cells…
Neuvivo has filed an application with the U.S. Food and Drug Administration (FDA) requesting the approval of its investigational therapy NP001 (sodium chlorite) to treat amyotrophic lateral sclerosis (ALS). The new drug application comes on the heels of combined data from Phase 2a (NCT01281631) and Phase…
Get regular updates to your inbox.